Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid Leukemia
Research Square
2023
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
venetoclax (VEN) and Azacitidine (AZA) combination have shown improved survival and excellent responses in patients with untreated Acute myeloid leukemia (AML). However, frequent dose reduction (or discontinuation) occurred due to therapy-related toxicity and may limit triplet combination tolerance. This study retrospectively analyzed the characteristics and outcomes of newly diagnosed AML patients who received 100mg VEN for 14 days combined with AZA at our institution. Overall, 36 patients were enrolled, the median age at diagnosis was 64 years; after a median follow-up of 15(range 4–29) months, median overall survival (OS) and progression-free survival (PFS) for the total cohort were 17 (4–29) months and 12 (1–28) months, and for patients achieving composite complete remission (CRc) were not reached. Overall response rate (ORR) was 69.4% and CRc rate were 66.7% for the total cohort. Subgroup analysis revealed that NPM1 mutations and FAB-M5 were associated higher response rates, while adverse ELN risk group predicted inferior response. ASXL1, NPM1 and IDH1/2 mutation was statistically significant impact the PFS duration. The most common adverse events were hematological, with grade 3 or 4 neutropenia, thrombocytopenia, and anemia reported in 36%, 25%, 44% of patients, respectively. In summary, the VEN combination regimen remains effective for newly diagnosed AML in the real world despite VEN dose reductions.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know